Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iReP: Neoadjuvant Atezolizumab and Chemotherapy in NSCLC
NCT04865250Phase 2Recruiting
- Sponsor
- Heidelberg University Hospital
- Start
- Jan 2021
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Heidelberg University Hospital. Started Jan 2021; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04865250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865250.